Company Overview - AtriCure is a leading innovator in surgical treatments for atrial fibrillation (Afib), with over 59 million people affected globally[18]. - AtriCure is recognized as a market leader in surgical Afib treatment and LAAM, with ongoing investments in clinical studies to validate the efficacy and safety of its products[29]. - AtriCure is the only company with FDA-approved devices for treating long-standing persistent Afib, including the Isolator Synergy Ablation and the EPi-Sense System[58]. Market Opportunity - The market for AtriCure's ablation products represents a significant growth opportunity, with less than 15% of potential candidates for surgical ablation currently being treated[23]. - Approximately 500,000 Afib patients are treated by catheter ablation annually in the U.S., a number expected to grow significantly[25]. - The annual diagnoses of Afib exceed one million in the United States, with a significant percentage of cases being under-diagnosed[21]. - Up to 50% of cardiac surgery patients without pre-operative Afib may develop post-operative Afib (POAF), indicating a large addressable market for preventative therapies[26]. Clinical Trials and Research - The Left Atrial Appendage Occlusion Study (LAAOS) III trial demonstrated a significant reduction in strokes when the LAA was managed during cardiac surgery[24]. - The BoxX-NoAF IDE trial aims to evaluate the safety and effectiveness of ablation and LAA exclusion in reducing post-operative Afib (POAF) in non-Afib patients[26]. - The ICE-AFIB clinical trial showed a 70% freedom from atrial fibrillation/atrial flutter/atrial tachycardia from 6 to 12 months, with a 30-day major adverse event rate of 9.3%[59]. - The LeAAPS IDE clinical trial completed enrollment of 6,573 patients across 139 centers globally in July 2025, focusing on prophylactic LAA exclusion for stroke reduction[53]. - The EPi-Sense System received FDA PMA approval for treating symptomatic, drug-refractory, long-standing persistent atrial fibrillation, demonstrating a 29% absolute difference in efficacy at 12 months compared to endocardial catheter ablation alone[59]. Product Innovations - AtriCure's EPi-Sense ablation system can double the success rate for long-standing persistent Afib patients when used in conjunction with catheter ablation[25]. - The cryoXT™ device was launched in September 2025 to manage post-operative pain following amputations, addressing the needs of over 180,000 amputations annually in the U.S.[28]. - The cryoSPHERE MAX probe reduces freeze times by 50% compared to the first-generation cryoSPHERE probe, showcasing advancements in pain management technology[37]. - The AtriClip LAA Exclusion System has treated more than 750,000 patients globally, making it the most widely sold LAA management device[38]. - The AtriClip FLEX-Mini device, launched in 2024, sets a new standard as the smallest surgical LAA management device on the market[39]. Regulatory and Compliance - AtriCure's products are subject to regulation by the FDA and comparable authorities in the EU and other countries[66]. - The company is an FDA-registered medical device manufacturer and certified to ISO 13485:2016, ensuring compliance with quality system requirements[89]. - The European Union's Medical Device Regulation (EU MDR) effective May 26, 2021, imposes stringent conformity assessment requirements for medical devices[79]. - The company has successfully participated in the Medical Device Single Audit Program (MDSAP), recognized in Australia, Brazil, Canada, Japan, and the United States[90]. Employee and Workplace Culture - AtriCure had approximately 1,350 employees as of December 31, 2025, with a voluntary turnover rate consistently at or below 10% over the last five years[92]. - The company has been recognized as a Top Workplace ten times in the past eleven years and has been voted a Great Place to Work for four consecutive years[94]. - AtriCure is committed to advancing Diversity, Equity, and Inclusion (DE&I) initiatives, earning recognition for providing opportunities for women[98]. - The company regularly analyzes and benchmarks its compensation and benefits programs to attract and retain top talent[99]. Sales and Market Access - AtriCure's sales team in the United States consists of approximately 330 employees, with an additional 75 employees in international markets[57]. - The company is actively pursuing market access in various geographies, focusing on obtaining reimbursement for therapies involving its devices[65]. - Medicare's reimbursement policies are significant for AtriCure, as a large percentage of its product users are Medicare beneficiaries[61]. - Hospital reimbursement rates for cardiac surgical ablation procedures are believed to be adequate to cover the cost of AtriCure's products[62]. Supply Chain and Manufacturing - AtriCure's manufacturing facilities are located in Ohio, where the majority of products are assembled, inspected, tested, and packaged[87]. - The company maintains inventory levels of components and raw materials to minimize supply chain risks and has not experienced significant product availability issues[88]. - The company conducts regular audits of suppliers for compliance with quality system requirements[89].

Fourth-quarter gross margin was 75%, up 45 basis points year over year, driven primarily by favorable product mix. AtriCure reported fourth-quarter net income of $1.8 million versus a $15.6 million net loss a year earlier, and adjusted EBITDA of $19.9 million versus $12.7 million in 2024. EPS was $0.04 and adjusted EPS was $0.06, compared with a loss per share of $0.33 and adjusted loss per share of $0.08 in the prior-year quarter.In the fourth quarter, worldwide revenue was $140.5 million, increasing 13.1% ...

分组1 - AtriCure reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.02 per share, and showing improvement from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +400.00% [1] - The company achieved revenues of $140.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.01% and increasing from $124.28 million year-over-year [2] - AtriCure has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 17.5% since the beginning of the year, compared to a decline of 0.1% in the S&P 500 [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at -$0.09 for the coming quarter and $0.02 for the current fiscal year [7] - The Medical - Products industry, to which AtriCure belongs, is currently ranked in the bottom 40% of Zacks industries, which may impact stock performance [8]

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAngie Wirick - CFODanny Stauder - Director of Equity Research in Medical TechnologyJohn McAulay - Associate VPMarissa Bych - Managing DirectorMike Carrel - President and CEOConference Call ParticipantsLily Lozada - Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMike Matson - Senior AnalystSuraj Kalia - Managing Director and Senior Analyst in Medical Tec ...

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAngie Wirick - CFODanny Stauder - Director of Equity Research in Medical TechnologyJohn McAulay - Associate VPMarissa Bych - Managing DirectorMike Carrel - President and CEOConference Call ParticipantsLily Lozada - Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMike Matson - Senior AnalystSuraj Kalia - Managing Director and Senior Analyst in Medical Tec ...

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Speaker10Good afternoon, and welcome to AtriCure's fourth quarter and full year 2025 earnings conference call. This call is being recorded for replay purposes, and at this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session following prepared remarks from AtriCure's management. I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory com ...

Exhibit 10.1 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT AND SECURITY AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT AND SECURITY AGREEMENT (this "Amendment"), dated as of January 9, 2026, is among ATRICURE, INC. (the "Company") and ATRICURE, LLC (together with the Company, the "Borrowers"), the other Loan Parties (if any) party hereto, the Lenders party hereto, the Issuing Bank and JPMORGAN CHASE BANK, N.A., as Administrative Agent (in such capacity, the "Administrative Agent") and an Issuing ...

Core Insights - The article discusses the importance of efficiency ratios in evaluating a company's potential for profitability and stock selection [2] Efficiency Ratios - Receivables Turnover measures a company's ability to collect debts and indicates quality customers; a high ratio is desirable [3] - Asset Utilization indicates how well a company converts assets into sales; a higher ratio suggests greater efficiency [4] - Inventory Turnover assesses a company's ability to manage inventory relative to sales; a high ratio indicates effective inventory management [5] - Operating Margin reflects a company's control over operating expenses; a higher margin suggests better efficiency compared to peers [6] Screening Criteria - The screening process included a favorable Zacks Rank of 1 (Strong Buy) to enhance profitability [7] - The criteria narrowed down over 7,906 stocks to 13 based on efficiency ratios exceeding industry averages [8] Selected Companies - AtriCure (ATRC) focuses on innovative surgical devices and has an average four-quarter earnings surprise of 67.1% [11] - REV Group (REVG) designs specialty vehicles and has an average four-quarter earnings surprise of 22.1% [12] - Oceaneering International (OII) provides offshore equipment and technology solutions, with an average four-quarter earnings surprise of 12.3% [13] - Analog Devices (ADI) manufactures semiconductor devices and has an average four-quarter earnings surprise of 5.8% [14]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Company Overview - AtriCure is focused on reducing the burden of atrial fibrillation (Afib) globally and alleviating pain after surgery [3] - The company aims to provide a comprehensive overview of its market opportunities and product portfolio [2] Market Opportunity - AtriCure identifies a significant market opportunity, estimating a potential annual market size of $10 billion [3] - The company emphasizes the strength of its product portfolio, which includes advanced technology and a robust pipeline supported by clinical evidence [3]